News

October 15th, 2005

In a collaboration with colleagues in Denmark and Germany, scientists at ReceptIcon recently achieved a major scientific breakthrough by demonstrating that the receptor megalin is required for specific delivery of androgens and estrogens into target tissues in vivo and that inactivation of this receptor pathway in animal models renders tissues insensitive to sex steroids.

This study was published in the prestigious scientific journal CELL and received wide-spread attention by editorial comments in the international scientific press including Nature.

Cell: Role of Endocytosis in Cellular Uptake of Sex Steroids

Cell: “Bound” to Work: The Free Hormone Hypothesis Revisited

Nature: Research highlights (Requires subscribtion or purchase)

ReceptIcon’s unique findings demonstrated the existence of active uptake pathways for sex steroids into target tissues and pave the way for developing novel therapeutic strategies to block delivery of androgens and estrogens to steroid-dependent tumors of the breast and prostate, among the most common types of cancers worldwide.

ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs.

The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.

Anders Nykjaer , CEO
an@recepticon.com
Phone - direct: +45 2899 2384